These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 16831938

  • 1. Bisphosphonates: from bench to bedside.
    Russell RG.
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG, Rogers MJ.
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [Abstract] [Full Text] [Related]

  • 5. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S, Kamiya S, Ono K.
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [Abstract] [Full Text] [Related]

  • 6. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [Abstract] [Full Text] [Related]

  • 7. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [Abstract] [Full Text] [Related]

  • 8. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP.
    J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
    [Abstract] [Full Text] [Related]

  • 10. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 11. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 12. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug 15; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 13. Physiology of the aging bone and mechanisms of action of bisphosphonates.
    Dominguez LJ, Di Bella G, Belvedere M, Barbagallo M.
    Biogerontology; 2011 Oct 15; 12(5):397-408. PubMed ID: 21695491
    [Abstract] [Full Text] [Related]

  • 14. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.
    Arch Biochem Biophys; 2000 Jan 01; 373(1):231-41. PubMed ID: 10620343
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 16. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
    Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH.
    Bone; 2006 May 01; 38(5):617-27. PubMed ID: 16046206
    [Abstract] [Full Text] [Related]

  • 17. Recent advances in understanding the mechanism of action of bisphosphonates.
    Coxon FP, Thompson K, Rogers MJ.
    Curr Opin Pharmacol; 2006 Jun 01; 6(3):307-12. PubMed ID: 16650801
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
    Ebetino FH, Sun S, Cherian P, Roshandel S, Neighbors JD, Hu E, Dunford JE, Sedghizadeh PP, McKenna CE, Srinivasan V, Boeckman RK, Russell RGG.
    Bone; 2022 Mar 01; 156():116289. PubMed ID: 34896359
    [Abstract] [Full Text] [Related]

  • 19. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
    Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ.
    Bone; 2005 Sep 01; 37(3):349-58. PubMed ID: 16006204
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B, Ling Chau JF, Wang X, Leong WF.
    J Cell Biochem; 2011 May 01; 112(5):1229-42. PubMed ID: 21465521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.